valproic acid glucuronide

UK cuts 2026 new-medicine rebate rate to 14.5% under VPAG

1 month ago talkbio0Tagged branded medicines, clawback rate, Drug Industry, drug price, Growth, Nance-Horan syndrome, rebate rate, United Kingdom, valproic acid glucuronide, Voluntary Scheme

United Kingdom; VPAG; Voluntary Scheme for Branded Medicines Pricing Access and Growth; rebate rate; clawback rate; new medicines; NHS; drug pricing; pharmaceutical industry; 2026

UK Pharma Trade Group Calls for Overhaul of Government’s Life Sciences Investment Evaluation and Medicines Pricing Schemes

4 months ago talkbio0Tagged ABPI, Biological Science Disciplines, Evaluation, government review, innovation, Investments, Nance-Horan syndrome, pharma trade group, Pricing, statutory scheme, UK, valproic acid glucuronide

UK life sciences; ABPI; VPAG; pharma trade group; investment evaluation; medicines pricing; government review; NHS; innovation; statutory scheme

UK Drugmakers and Government at Impasse Over New Medicine Rebate Scheme

5 months ago talkbio0Tagged Drug Industry, drugmakers, Government, Health Services, National, Mediation, rates, statutory scheme, UK, valproic acid glucuronide

UK; drugmakers; medicine rebate; government negotiations; VPAG; statutory scheme; pharmaceutical industry; National Health Service; rebate rates